Bypassing The Challenges Of Paper-Based Validation

Theragent is a biotechnology startup and contract development and manufacturing organization (CDMO) dedicated to developing and producing cell and gene immunotherapies for treating cancer and rare diseases. To propel its growth and establish itself as a leading CDMO, Theragent aimed to swiftly operationalize its cutting-edge smart manufacturing facility without compromising compliance or safety. Achieving this goal necessitated considerable validation effort.

Here, Chief Operating Officer Jeff Masten underscores the importance of implementing ValGenesis VLMS from the outset of operations. This strategic decision was driven by the company's commitment to achieving and maintaining a continuous validation process, instilling confidence in clients who rely on Theragent to safeguard their valuable assets. Explore the challenges of paper-based validation, Thergent's vendor selection process, the implementation process, and how ValGenesis is helping Theragent to build the facility of the future.